Listen in as Sara Struwe, President and CEO of the Spina Bifida Association, and Laura Carlson, Volunteer Research Coordinator, as they further discuss Genetically Targeted Technologies (GTTs), what they mean to the Spina Bifida community, and the MINI Act. 

What is the MINI Act?

Bipartisan legislation known as the Maintaining Investment in New Innovations Act (S. 476 / H.R. 5547) would tweak how GTTs are impacted by the Inflation Reduction Act. The MINI Act would group GTTs with other sophisticated medications, such as biologics, giving them a longer timeline before coming up for Medicare price negotiation. The adjusted timeline would encourage and incentivize ongoing research and development.

How does it affect people with Spina Bifida?

New advances in medical technology such as genetically targeted technologies, known as GTTs, brings hope for new treatments to improve the quality of life for those living with Spina Bifida.

Download the information sheet >>

What Can You Do?

Send messages to your members of Congress asking them to support the MINI Act.

In partnership with Novartis